Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas

Journal of Korean Medical Science

Volumn 20, Issue 5, 2005, Pages 853-859

  Choi, Yoon La ^a   Mi, Kyung Kim ^a   Suh, Jin Won ^a   Han, Joungho ^a   Jung, Han Kim ^a   Jung, Hyun Yang ^a   Seok, Jin Nam ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Cadherins; HBME 1 antigen; Keratin; Thyroid Neoplasms; Thyroid nuclear factor 1

Indexed keywords

EID: 27744498576     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2005.20.5.853     Document Type: Article

References (23)

1. Rosai J. Thyroid gland. In: Rosai J, editor, Rosai and Ackermann's Surgical Pathology, 9 ed. Phildelphia: Elsevier, 2004; 515-94.
2. van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol 1998; 18: 93-7.
3. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 2003; 14: 55-60.
4. Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 1997; 10: 668-74.
5. Cameron BR, Berean KW. Cytokeratin subtypes in thyroid tumors: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma. J Otolaryngol 2003; 32: 319-22.
6. Kragsterman B, Grimelius L, Wallin G, Werga P, Johansson H. Cytokeratin 19 expression in papillary thyroid carcinoma. Appl Imunohistochem Mol Morphol 1999; 7: 181-5.
7. Shin E, Chung WY, Yang WI, Park CS, Hong SW. RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation. J Korean Med Sci 2005; 20: 98-104.
8. Baloch ZW, Abraham S, Roberts S, LiVolsi VA. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol 1999; 30: 1166-71.
9. Liberman E, Weidner N. Papillary and follicular neoplasms of the thyroid gland. Differential immunohistochemical staining with high-molecular-weight keratin and involucrin. Appl Immunohistochem Mol Morphol 2000; 8: 42-8.
10. Yap AS, Stevenson BR, Keast JR, Manley SW. Cadherin-mediated adhesion and apical membrane assembly define distinct steps during thyroid epithelial polarization and lumen formation. Endocrinology 1995; 136: 4672-80.
11. Brabant G, Hoang-Vu C, Behrends J, Cetin Y, Potter E, Dumont JE, Maenhaut C. Regulation of the cell-cell adhesion protein, E-cadherin, in dog and human thyrocytes in vitro. Endocrinology 1995; 136: 3113-9.
12. Brabant G, Hoang-Vu C, Cetin Y, Dralle H, Scheumann G, Molne J, Hansson G, Jansson S, Ericson LE, Nilsson M. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 1993; 53: 4987-93.
13. Soares P, Berx G, van Roy F, Sobrinho-Simoes M. E-cadherin gene alterations are rare events in thyroid tumors. M J Cancer 1997; 70: 32-8.
14. Scheumman GF, Hoang-Vu C, Cetin Y, Gimm O, Behrends J, von Wasielewski R, Georgii A, Birchmeier W, von Zur Muhlen A, Dralle H. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab 1995; 80: 2168-72.
15. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simoes M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 2003; 42: 580-7.
16. von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Potter E, Brabant G, Georgii A. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997; 57: 2501-7.
17. Rosia J, Carcangiu ML, Delellis RA. Atlas of Tumor Pathology: Tumors of the thyroid gland. AFIP third series, fascicle 5, 1992.
18. LiVolsi VA. Surgical pathology of the thyroid. In: Saunders, editor. Philadelphia, PA, 1990.
19. Cerrato A, Fulciniti F, Avallone A, Benincasa G, Palombini L, Grieco M. Beta- and gamma-catenin expression in thyroid carcinomas. J Pathol 1998; 185: 267-72.
20. Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB, Saji M, Zeiger MA, Zimmer SG, Baylin SB. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res 1998; 58: 2063-6.
21. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999; 59: 1811-5.
22. Lonigro R, De Felice M, Biffali E, Macchia PE, Damante G, Asteria C, Di Lauro R. Expression of thyroid transcription factor 1 gene can be regulated at the transcriptional and posttranscriptional levels. Cell Growth Differ 1996; 7: 251-61.
23. Katoh R, Kawaoi A, Miyagi E, Li X, Suzuki K, Nakamura Y, Kakudo K. Thyroid transcription factor-1 in normal, hyperplastic, and neo-plastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization. Mod Pathol 2000; 13: 570-6.